FDA and CBD: Where Things Stand

CBD can be widely available and still sit within an unsettled regulatory framework. That is the central distinction behind the question “Is CBD FDA-approved?” Availability, hemp status, and FDA approval are different things.

For consumers, the practical questions are straightforward: What does the FDA oversee? Which product claims deserve scrutiny? And what can a label or laboratory report actually tell you?

This 2026 overview explains the FDA’s published framework and the distinctions that matter when evaluating CBD products. Federal policy and state requirements can change, so check current agency guidance and your state’s law before purchasing, traveling with, or selling CBD.

Hemp legality and FDA compliance are separate questions

The 2018 Farm Bill changed federal law by removing hemp, as federally defined, from the Controlled Substances Act’s definition of marijuana. Its hemp definition used a delta-9 THC threshold of no more than 0.3% on a dry-weight basis.

That was an important agricultural and controlled-substance change. It was not blanket permission to put CBD into every consumer product.

The legislation preserved the FDA’s authority over products regulated under the Federal Food, Drug, and Cosmetic Act. Consequently, a hemp-derived ingredient can raise separate questions under food, supplement, drug, or cosmetic law.

Federal hemp definitions and implementation requirements also need to be checked against subsequent legislation. In 2026, the original Farm Bill language should be treated as background—not a substitute for verifying the law currently applicable to a particular product.

“Derived from legal hemp” does not, by itself, establish FDA compliance.

What the FDA actually regulates

The FDA’s role depends on how a product is formulated, presented, and intended to be used. A CBD oil, beverage, capsule, and skin lotion do not necessarily fall into the same regulatory category.

The agency considers labeling, advertising, ingredients, and intended use. Claims on a website or social media account can matter alongside wording printed on packaging.

### Approval belongs to a specific product

The FDA has approved a prescription medicine containing purified CBD. That approval applies to that medicine and its authorized labeling—not to CBD as an ingredient in every commercial setting.

A retail CBD product cannot borrow that approval. Neither can a seller imply that using a similar cannabinoid means its product has undergone the same review.

Similarly, statements such as “FDA-registered facility” do not mean that the FDA has approved the finished product. Facility registration and product approval are distinct regulatory concepts.

Why CBD foods and supplements remain complicated

Under the FDA’s published position, CBD generally cannot lawfully be marketed as a dietary supplement. The agency has also stated that adding CBD to food introduced into interstate commerce is prohibited under the relevant federal provisions.

These conclusions involve statutory provisions concerning substances investigated or approved as drugs. The issue is therefore more complicated than whether a manufacturer follows ordinary supplement-labeling conventions.

Putting “dietary supplement” on a bottle does not resolve the underlying question. Nor does selling a CBD beverage through a familiar retail channel establish federal compliance.

### The FDA has called for a different framework

In January 2023, the FDA announced that existing food and dietary supplement frameworks were not appropriate for CBD. It said a new regulatory pathway would be needed and expressed a willingness to work with Congress.

The agency identified concerns involving long-term use, potential interactions, and exposure among vulnerable populations.

That announcement was not a new approval system or permission to market products under one. Readers following developments in 2026 should distinguish proposals, agency statements, enacted legislation, and rules that have actually taken effect.

Cosmetics have different rules—not an exemption

CBD-containing cosmetics raise a different set of questions from ingestible products. The FDA explains that cosmetic ingredients generally do not require premarket approval, with exceptions such as certain color additives.

However, cosmetics must still meet applicable safety and labeling requirements. Lack of routine premarket approval is not the same as an FDA finding that a particular product is safe.

Intended use also matters. A product presented only for cosmetic purposes may be regulated differently from one advertised with disease-related or body-function claims.

For consumers, this means that a topical format is not a regulatory shortcut. Evaluate what the product says it does, how its ingredients are disclosed, and whether the manufacturer provides appropriate directions and cautions.

Marketing claims are a major enforcement concern

The FDA has issued warning letters to CBD sellers over issues including unapproved drug claims and violations involving foods or supplements. These letters are public records and offer useful examples of the agency’s reasoning.

The Federal Trade Commission also oversees advertising practices. Its Health Products Compliance Guidance explains that health-related advertising requires appropriate scientific substantiation.

Together, these responsibilities make the overall marketing message important—not just a carefully worded label.

Be cautious around:

• Promises of guaranteed outcomes.
• Claims suggesting a retail CBD product replaces professional care.
• Testimonials presented as proof of disease-related benefits.
• Statements implying FDA approval without identifying an approved product.

A disclaimer does not automatically neutralize a misleading claim. Neither does attributing a claim to a customer rather than the company.

The absence of a warning letter should not be interpreted as approval, certification, or a complete compliance review.

What the research does—and does not—establish

Researchers are studying CBD across multiple contexts, but findings cannot automatically be transferred from one formulation to another.

Research may involve pharmaceutical-grade material, tightly controlled amounts, or populations unlike typical retail consumers. A study of CBD does not establish that every product containing CBD produces the same results.

The FDA’s consumer information also identifies potential safety concerns, including interactions with medications, liver injury, and changes in alertness. These concerns are reasons to approach CBD thoughtfully rather than assume that a plant-derived ingredient is inherently risk-free.

If you take medication, have a health condition, or are considering CBD during pregnancy or breastfeeding, seek guidance from a qualified healthcare professional. FDA guidance advises against CBD use during pregnancy and breastfeeding.

“More research is needed” should be a meaningful limitation—not a preface to an unsupported promise.

What laboratory reports can tell you

Independent testing can improve transparency, but it cannot make an otherwise noncompliant product FDA-approved.

A certificate of analysis, often called a COA, can show what a laboratory measured in a submitted sample. Depending on the testing performed, that may include cannabinoid concentrations and results for contaminants such as pesticides, heavy metals, residual solvents, or microorganisms.

A useful review includes checking:

• Whether the report matches the product’s batch or lot.
• Which tests were performed.
• Whether results include units and relevant detection limits.
• Whether the laboratory and report date are clearly identified.

A COA remains a snapshot of testing, not proof of every claim on a website.

Divine Earth’s products are broad-spectrum, with 0.0% THC. That product description should be read alongside batch-specific documentation. More generally, “not detected” on a report means below the method’s detection capability—not proof of absolute absence under every possible test.

State law still matters in 2026

Federal oversight is only part of the picture. States may impose their own requirements for product categories, age restrictions, testing, labeling, registration, and cannabinoid content.

Permission in one state does not establish permission in another. Online availability also does not prove that a product may lawfully be shipped to every destination.

Before buying or traveling with CBD, check current information from the relevant state agriculture department, health department, or cannabinoid regulator. For business decisions, seek qualified legal advice rather than relying on a retailer’s summary.

The USDA’s hemp production framework, FDA product requirements, and state consumer-product rules address different parts of the supply chain. No single approval or document necessarily answers every legal question.

The takeaway

CBD’s regulatory status cannot be reduced to “legal hemp” or “FDA-approved.” Product category, intended use, marketing claims, and current federal and state requirements all matter.

Look for measured language, accessible batch testing, and clear labeling. Treat regulatory claims with the same care as wellness claims—and verify current law rather than assuming widespread availability means official approval.